IP Library › Granted Patent US 12,728,276
Granted Patent B2
US 12,728,276 · App. 18/683,963 · Granted Sep 8, 2026

Implantable system and method for providing anti-tachycardia and/or shock therapy

Inventors: Thomas Doerr (Berlin, DE); Ingo Weiss (Berlin, DE)
Assignee: BIOTRONIK SE & Co. KG
A61N1/39622A61N1/3621A61N1/37217A61N1/3925
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,728,276
App. No.
18/683,963
Granted
Sep 8, 2026
Kind
B2
Abstract

An implantable system for providing anti-tachycardia and/or shock therapy, comprising an implantable pacing device, in particular an implantable leadless pacemaker, and an implantable cardioverter defibrillator, in particular a non-transvenous implantable cardioverter defibrillator, wherein the implantable pacing device is configured to detect a tachycardia and to provide anti-tachycardia pacing, wherein the implantable pacing device is further configured to signal an unavailability of anti-tachycardia pacing to the implantable cardioverter defibrillator, and wherein the implantable cardioverter defibrillator is configured, in response to the signal of the implantable pacing device, to adjust predetermined shock therapy parameters and/or to send a message to a remote monitoring system. A computer implemented method for providing anti-tachycardia and/or shock therapy, a computer program and a computer readable data carrier are also provided.

Claims (19)

1 . Implantable system for providing anti-tachycardia and/or shock therapy, comprising: an implantable pacing device, in particular an implantable leadless pacemaker, and an implantable cardioverter defibrillator, in particular a non-transvenous implantable cardioverter defibrillator, wherein the implantable pacing device is configured to detect a tachycardia and to provide anti-tachycardia pacing, wherein the implantable pacing device is further configured to signal an unavailability of anti-tachycardia pacing to the implantable cardioverter defibrillator, and wherein the implantable cardioverter defibrillator is configured, in response to the signal of the implantable pacing device, to adjust predetermined shock therapy parameters related to delay of shock therapy.

2 . Implantable system of claim 1 , wherein the implantable pacing device is configured to stimulate at least one ventricle of a human or animal heart, and wherein the implantable pacing device comprises a configurable tachyarrhythmia detection unit configured to detect a tachycardia and further comprises an anti-tachycardia pacing timing unit configured to deliver an anti-tachycardia pacing sequence in response to tachycardia detection.

3 . Implantable system of claim 1 , wherein the implantable pacing device comprises a fault detection device configured to detect the unavailability of anti-tachycardia pacing, in particular due to a battery exhaustion and/or fault conditions of the implantable pacing device.

4 . Implantable system of claim 1 , wherein the implantable pacing device comprises a first control unit configured to block anti-tachycardia pacing delivery after detection of battery exhaustion and/or fault conditions and is configured to signal the unavailability of anti-tachycardia pacing to the implantable cardioverter defibrillator.

5 . Implantable system of claim 1 , wherein the implantable pacing device is configured to detect a first stage of battery depletion, in which anti-tachycardia pacing is unavailable but anti-bradycardic pacing is available, and wherein the implantable pacing device is configured to detect a second stage of battery depletion, in which both anti-tachycardia pacing and anti-bradycardic pacing are unavailable.

6 . Implantable system of claim 1 , wherein the implantable pacing device is configured to signal the implantable cardioverter defibrillator by means of intra-body-communication, in particular by means of electrical pulses, communication and/or radio signals.

7 . Implantable system of claim 1 , wherein the implantable pacing device is configured to signal the unavailability of anti-tachycardia pacing to the implantable cardioverter defibrillator by the implantable pacing device detecting an absence of expected anti-tachycardia pacing, in particular if anti-tachycardia pacing is not provided for a predetermined time period in case of a detected tachycardia.

8 . Implantable system of claim 1 , wherein the implantable cardioverter defibrillator comprises at least one receiving unit configured to receive information indicating the unavailability of anti-tachycardia pacing and/or anti-bradycardic pacing, from the implantable pacing device.

9 . Implantable system of claim 8 , wherein the implantable cardioverter defibrillator comprises a second control unit configured to adjust a therapeutic and/or diagnostic behavior of the implantable cardioverter defibrillator upon receiving the information from the implantable pacing device and/or to forward the received information to the remote monitoring system.

10 . Implantable system of claim 9 , wherein the implantable cardioverter defibrillator is configured to detect the information if one or more expected anti-tachycardia pacing attempts are not sensed by the implantable cardioverter defibrillator.

11 . Implantable system of claim 1 , wherein the implantable cardioverter defibrillator is configured to shorten or suppress a defibrillation delay when it is detected that anti-tachycardia pacing delivery is unavailable.

12 . Implantable system of claim 1 , wherein the implantable cardioverter defibrillator is configured to adjust at least one zone boundary for tachycardia detection when it is detected that anti-tachycardia pacing delivery is unavailable.

13 . Computer implemented method for providing anti-tachycardia and/or shock therapy, comprising the steps of:

providing an implantable system for providing anti-tachycardia and/or shock therapy, comprising an implantable pacing device, in particular an implantable leadless pacemaker, and an implantable cardioverter defibrillator, in particular a non-transvenous implantable cardioverter defibrillator;

detecting a tachycardia and providing anti-tachycardia pacing, by means of the implantable pacing device;

signaling an unavailability of anti-tachycardia pacing to the implantable cardioverter defibrillator by means of the implantable pacing device; and

adjusting predetermined shock therapy parameters related to delay of shock therapy by the implantable cardioverter defibrillator in response to the signal of the implantable pacing device.

14 . A non-transitory computer program with program code to perform the method of claim 13 when the computer program is executed on a computer.

15 . Computer-readable data carrier containing program code of a non-transitory computer program for performing the method of claim 13 when the computer program is executed on a computer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2024
From: DOERR, THOMAS; WEISS, INGO, DR.
To: BIOTRONIK SE & CO. KG
Reel/Frame 067856/0931 →
Priority Claims (1)
EP 21194954 · Sep 6, 2021 · regional
Continuity (1)
Related Publication 20240359023A1 · Oct 31, 2024
References Cited (13)
US 5836971A · Starkweather · 1998 [cited by examiner]
US 8744572B1 · Greenhut · 2014 [cited by examiner]
US 10265534B2 · Greenhut et al. · 2019 [cited by applicant]
US 20150360041A1 · Stahmann · 2015 [cited by examiner]
US 20160008615A1 · Stahmann et al. · 2016 [cited by applicant]
US 20170312514A1 · Hareland · 2017 [cited by examiner]
US 20180036547A1 · Reddy · 2018 [cited by applicant]
US 20180243578A1 · Volosin · 2018 [cited by applicant]
US 20190160285A1 · Huelskamp et al. · 2019 [cited by applicant]
US 20200254262A1 · Demmer · 2020 [cited by examiner]
WO 2016126613A1 · 2016 [cited by applicant]
Extended European Search Report mailed Feb. 23, 2022, by the European Patent Office for Application No. EP21194954.0. (8 pages). [cited by applicant]
International Search Report (PCT/ISA/210) and Written Opinion (PCT/ISA/237) mailed Nov. 17, 2022, by the European Patent Office for International Application No. PCT/EP2022/073113. (17 pages). [cited by applicant]